Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Maduración del eje reproductivo en los primeros años posmenárquicos

4 de noviembre de 2026 actualizado por: National Institute of Environmental Health Sciences (NIEHS)

Maduración del eje reproductivo en los primeros años posmenárquicos: un estudio piloto

Background:

Most adult women with irregular periods of unknown cause report symptoms dating back to early adolescence. This study aims to learn how girls' periods change in the 2 years after their first period. We are also looking at girls who may have a condition called PCOS. This will help researchers learn what healthy puberty looks like and how they can spot signs of hormone problems early on.

Objective:

To learn how long it takes girls to develop regular menstrual cycles after their first period.

Eligibility:

Healthy girls ages 8-14 who either (1) haven't had their first period but show signs of puberty, such as breast development and hair in the genital area; or (2) had their first period in the past 6 months

Girls at risk for PCOS age 8-14 who have a mom or sister with PCOS

Girls with irregular menstrual cycles age 11-17.5

To compare with the girls, we are looking at women >=18-34 years old with PCOS,

Healthy women >= 18-34 years old without PCOS,

and Mothers of pediatric participants age 18-65

Design:

Both parents or guardians must allow their daughter to participate. They must attend all study visits with her.

Participants will first be screened by phone. Those who qualify will be screened in person. They will have a physical exam. They will give blood and urine samples. They will have an ultrasound of their abdomen. They will fill out questionnaires. They will sit in a BOD POD for 6 minutes: This is an egg- shaped machine that takes body measurements. They have the option to provide DNA samples.

Participants will have sets of visits at home or at the clinic about every 6 months. The number of visits in each set will depend on their menstrual cycle. Then they will have a final visit. Visits will include repeats of the screening tests. There are additional parts that participants may choose to be involved in depending on how involved they want to be.

At home, participants will collect their urine daily to measure hormones. They will keep a diary of their periods.

Adults: Women with known PCOS will complete the same Screening Visit as the girls and will collect dried urine specimens at home for 8 weeks;

The Healthy control women group will complete the same Screening Visit as the girls and collect dried urine specimens at home for 2 menstrual cycles;

The Mothers of pediatric participants group will complete a Screening Visit (informed consent, urine pregnancy test) and collect vaginal swab specimens at home for 2 menstrual cycles (approx. 8 weeks).

Descripción general del estudio

Descripción detallada

The broad goal of these studies is to determine the physiologic and pathophysiologic underpinnings of irregular menstrual cycles among adolescents in general and those with increased genetic risk for polycystic ovarian syndrome (PCOS) in the early postmenarchal

period. Irregular menstruation affects > 2.5 million reproductive-age women in the US each year1. Most adult women with oligomenorrhea of unknown etiology reporting symptoms dating back to early adolescence. Importantly, irregular menstrual cycles during the teenage years may be a harbinger of future health risks extending beyond the reproductive system; among the nearly 80,000 female participants the Nurses' Health Study II, those with irregular and long cycles during adolescence and adulthood had a greater risk of premature mortality, particularly related to cardiovascular disease. While a period of cycle irregularity is well-described in the first few years after menarche, a lack of understanding of the basic mechanisms of normal reproductive axis development in the post-menarchal female has hampered our ability to distinguish abnormal from normal developmental trajectories. Moreover, the commonly held belief that menstrual irregularity among teenage girls is normal has also delayed detection of pathology in reproductive development, precluding institution of early preventative strategies to curtail future reproductive morbidity.

Tipo de estudio

De observación

Inscripción (Estimado)

400

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: NIEHS Join A Study Recruitment Group
  • Número de teléfono: (855) 696-4347
  • Correo electrónico: myniehs@nih.gov

Copia de seguridad de contactos de estudio

  • Nombre: Natalie D Shaw, M.D.
  • Número de teléfono: (984) 287-3716
  • Correo electrónico: natalie.shaw@nih.gov

Ubicaciones de estudio

    • North Carolina
      • Research Triangle Park, North Carolina, Estados Unidos, 27709
        • Reclutamiento
        • NIEHS Clinical Research Unit (CRU)
        • Contacto:
          • NIEHS Join A Study Recruitment Group
          • Número de teléfono: 855-696-4347
          • Correo electrónico: myniehs@nih.gov

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

8 años a 65 años (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Femenino

Método de muestreo

Muestra no probabilística

Población de estudio

Healthy early post-menarchal girls age 8-<15 years; PCOS women and girls with first degree relatives with PCOS; Healthy women 18-34 years; Late post-menarchal girls age 11-<17.5; healthy pre-menarchal girls age 8-<14.5; mothers of pediatric participants age 18-65

Descripción

  • Part 1 - Pre-menarche monitoring ("holding pattern"):

Inclusion Criteria:

  • Age 8-14.5 years old
  • Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
  • Some breast development
  • Pre-menarche

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).
  • Planning to move more than 60 miles from the CRU within the next 2 to 3 years
  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder
  • Excessive exercise (defined as running >20 miles per week or its equivalent)
  • Pregnancy

Part 2 - Post-menarche cycle tracking:

Inclusion Criteria:

  • Age at menarche 10-14.5 years old
  • Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
  • Approximately < 6 months post-menarchal (will typically have completed 4 or fewer menstrual cycles)
  • Biochemical criteria: normal thyroid hormone, prolactin, and testosterone levels

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).

  • Planning to move more than 60 miles from the CRU within the next 2 to 3 years

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.

  • First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder

  • Excessive exercise (defined as running >20 miles per week or its equivalent)

  • Anemia (defined as hemoglobin <12.0 g/dl)

    --Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.

  • Pregnancy

Part 3 - Intensive monitoring of ovarian follicle growth

Inclusion Criteria:

  • Age at menarche 10-14.5 years old
  • Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
  • Within 1 year of menarche
  • Biochemical criteria: normal thyroid hormone, prolactin, and testosterone levels

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 1-2 years (e.g. birth control pills, biotin supplements).

  • Planning to move more than 60 miles from the CRU within the next year

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.

  • First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder

  • Excessive exercise (defined as running >20 miles per week or its equivalent)

  • Anemia (defined as hemoglobin <12.0 g/dl)

    --Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.

  • Pregnancy

Part 4 - Late Post-menarche cycle tracking:

Inclusion Criteria:

  • Age 11-17.5 years old
  • Approximately 2-5 years post-menarchal
  • Biochemical criteria: normal thyroid hormone and prolactin

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).

  • Planning to move more than 60 miles from the CRU within the next 6 months

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.

  • Anemia (defined as hemoglobin <12.0 g/dl)

    --Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.

  • Pregnancy

Adolescent girls, at-risk daughters, or sisters of women with PCOS

The girls with mothers or sisters with PCOS group will complete the Screening Visit and Parts 1-3. The same inclusion and exclusion criteria apply for Parts 1, 2, and 3 as stated above except that these individuals must have a first-degree relative with PCOS and they can have high androgen levels, excess body hair, and severe acne at screening.

Women with known PCOS (activities for 8 weeks only)

Inclusion Criteria:

  • Age >=18-34 years old
  • PCOS diagnosis
  • at least 3-years post-menarchal with irregular menstrual cycles
  • Biochemical (blood) or clinical signs of high androgen levels

Exclusion Criteria:

  • Cannot be taking any medications that affect reproductive or metabolic hormones (e.g. birth control pill, biotin supplements, spironolactone, metformin).
  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • Pregnancy

Healthy control women (Activities for 2 menstrual cycles)

Inclusion Criteria:

  • Age >=18-34 years old
  • at least 3-years post-menarchal with regular menstrual cycles every 21-35 days

Exclusion Criteria:

  • Cannot be taking any medications that affect reproductive or metabolic hormones (e.g. birth control pill, biotin supplements, spironolactone, metformin).
  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • PCOS diagnosis or first-degree relative with disorder
  • Pregnancy

Mothers of pediatric participants (Activities for 8 weeks / 2 menstrual cycles)

Inclusion Criteria:

  • Age >=18-65 years old
  • Biological mother of A Girl's First Period participant

Exclusion Criteria:

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • Pregnancy

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
At-risk girls

Girls with first degree relative diagnosed with Polycystic Ovary Syndrome (PCOS) age 8-<15

early post-menarche girls

Healthy, early post-menarchal girls age 8-<15

Healthy control women

Women age >18-34 without PCOS at least 3-years post-menarchal with regular menstrual cycles every 21-35 days

late post-menarche girls

Late post-menarchal girls age 11-<17.5 (gynecological age 2-5)

Mothers of pediatric study participants

Mothers age 18-65 whose daughter has provided at least one vaginal swab sample for the First Period study.

pre-menarche girls

Healthy, pre-menarchal girls age 8-<14.5

Women with PCOS

Women diagnosed with PCOS >18-34 at least 3-years post-menarchal with irregular menstrual cycles

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To determine the time from menarche to regular ovulatory cycles, defined as two consecutive ovulatory cycles in girls of variable genetic risk for PCOS
Periodo de tiempo: Defined as two consecutive ovulatory cycles with normal (10-14 day) luteal phase length during the first two post-menarchal years

We hypothesize that the temporal sequence of reproductive maturation will consist of anovulatory cycles (representing a time of unopposed estrogen exposure), ovulatory cycles with a short luteal phase (estrogen with low progesterone exposure), and finally, ovulatory cycles with a normal luteal phase length (estrogen action fully counterbalanced by progesterone action)

Defined as two consecutive ovulatory cycles with normal (10-14 day) luteal phase length during the first two post-menarchal years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Natalie D Shaw, M.D., National Institute of Environmental Health Sciences (NIEHS)

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de diciembre de 2019

Finalización primaria (Estimado)

1 de julio de 2029

Finalización del estudio (Estimado)

1 de julio de 2029

Fechas de registro del estudio

Enviado por primera vez

13 de junio de 2019

Primero enviado que cumplió con los criterios de control de calidad

13 de junio de 2019

Publicado por primera vez (Actual)

14 de junio de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

3 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 190110
  • 19-E-0110

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

It is not yet known if there will be a plan to make IPD available

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir